By: Julie Lang, MD
Date. 12/07/2023
Julie Lang, MD, a medical professional known for expertise in breast cancer research, has developed the Mechanical Conditioning Score (MCS), a test for identifying early-stage breast cancer patients with potential poor prognoses.
The MCS evaluates mechanical factors and markers in breast tissues, such as tissue stiffness, cellular alignment, and extracellular matrix composition. It aids in predicting patient prognoses and informing treatment decisions.
In terms of antifibrotic therapy, Lang’s research identifies how the MCS determines patients likely to respond to such interventions. By pinpointing individuals with increased tissue stiffness and fibrotic changes, the MCS becomes a tool for tailoring treatment strategies for early-stage breast cancer, potentially impacting patient outcomes.
Additionally, Lang’s research incorporates Circulating Tumor Cells (CTCs) as a surrogate for breast cancer prognosis and therapy response. Combining MCS with CTC analysis provides a comprehensive understanding of the disease, enhancing prognostic value and offering real-time assessment.
The association between MCS and CTCs refines prognostication and guides decisions on therapeutic interventions, contributing to a holistic approach to patient management and monitoring. Julie Lang, MD’s work underscores the potential of the Mechanical Conditioning Score in changing how early-stage breast cancer is diagnosed, prognosed, and treated, offering insights into precision medicine in oncology.